Table 1 Demographic and clinical characteristics. The p-values for gender were obtained using chi-square tests for patients with migraines without aura group and the healthy controls. The p-values for age were obtained using Mann–Whitney U Tests for the MwoA patients and HCs. The p-values for the anxiety status were obtained using paired samples t-test for the pre- and post-taVNS patients. The p-values for the headache duration, headache attacks, headache intensity, depression status, and quality of life were obtained using Wilcoxon signed rank tests for the pre- and post-taVNS patients. SD standard deviation, MwoA migraine without aura, HCs healthy controls, taVNS transcutaneous auricular vagus nerve stimulation, post-taVNS after taVNS treatment, pre-taVNS before taVNS treatment; a, chi-square test; b, Mann–Whitney U Tests; c, Wilcoxon signed rank tests; d, paired samples t-test.
Characteristics | MwoA | HCs | p value | |
|---|---|---|---|---|
Gender (male/female) | 10/25 | 14/24 | 0.45a | |
Age | 31.97 ± 6.78 | 32.00 ± 11.16 | 0.16b | |
pre-taVNS | post-taVNS | |||
Headache intensity (mean ± SD) | 48.14 ± 17.13 | 27.71 ± 20.78 | < 0.001c | |
Anxiety status (mean ± SD) | 39.55 ± 5.56 | 36.93 ± 6.39 | 0.002d | |
Depression status (mean ± SD) | 41.54 ± 5.23 | 38.32 ± 5.58 | < 0.001c | |
Quality of life for migraine (mean ± SD) | 60.40 ± 9.99 | 72.45 ± 8.89 | < 0.001c | |
Headache duration (h) (mean ± SD) | 53.22 ± 49.19 | 30.91 ± 45.71 | < 0.001c | |
Headache attacks (mean ± SD) | 3.89 ± 2.30 | 2.69 ± 2.31 | 0.009c | |